4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205

News   Dec 12, 2014

 
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
 
 
 

RELATED ARTICLES

Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors

News

A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.

READ MORE

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

Glythera Appoints Chief Scientific Officer and Strengthens SAB

News

Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE